Background Real-world information regarding the use of direct oral anticoagulants therapy
and the outcome in patients with renal dysfunction is limited. Objectives To evaluate the …

The use of direct oral anticoagulants for stroke prevention in patients with non-valvular atrial
fibrillation (NVAF) is robust. However, the efficacy and safety of different dosage in patients …

Background: Patients with advanced renal dysfunction were mostly excluded from clinical
trials that evaluated the benefit of novel oral anticoagulants (NOACs) in patients with atrial …

Importance Renal impairment confers an increased risk of stroke, bleeding, and death in
patients with atrial fibrillation. Little is known about the efficacy and safety of apixaban in …

Background and Objectives: Real-world evidence of apixaban treatment in patients with
chronic kidney disease remains scarce. This study aimed to compare the relative risk of …

Aims Atrial fibrillation (AF) is common among patients with impaired renal function.
Apixaban, a novel oral anticoagulant with partial renal excretion, was compared with …

Background: Compared with the general population, patients with advanced chronic kidney
disease have a> 10-fold higher burden of atrial fibrillation. Limited data are available …

BACKGROUND: Recommendations for apixaban dosing on the basis of kidney function are
inconsistent between the US Food and Drug Administration and European Medicines …

Background: Patients with end-stage kidney disease (ESKD) on dialysis were excluded from
clinical trials of direct oral anticoagulants for atrial fibrillation (AF). Recent data have raised …

Apixaban is prescribed for stroke prevention in nonvalvular atrial fibrillation (NVAF) in
patients with varying degrees of renal dysfunction. While pharmacokinetic data support …